Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives $40.42 Consensus Price Target from Brokerages
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to […]
